Form 4: Bioxytran Director Anders Utter Acquires Shares in Company

Bioxytran director Anders Utter acquired 97,535 shares of the company's stock at a price of $0.315 per share on January 6, 2025.

Summary

• Anders Utter, a director at Bioxytran, Inc., acquired 97,535 shares of the company's stock on January 6, 2025.
• The shares were purchased at a price of $0.315 per share.
• Following the transaction, Mr. Utter directly owns 333,992 shares of Bioxytran stock.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It reports a transaction by a director, which could be seen as positive, but it is a standard filing and does not indicate any significant change in the company's outlook.

Positives

• The director's purchase of shares could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is required when company insiders trade shares. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The transaction is typical of insider trading activity and is not unusual.

Stakeholder Impact

• The share purchase may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Bioxytran, insider trading, share acquisition, director, BIXT, Anders Utter